Theme: Innovations and Novel Approaches in Mucosal Immunology

Mucosal Immunology 2017

Mucosal Immunology 2017

Track 1: Mucosal Diseases

Diseases of the mucous membranes are frequently more difficult to diagnose than skin diseases. This is somewhat due to alteration of the primary lesion either by the continuous mouth moisture or by different elements in the mouth or those reaching in the mouth from outside, either through food, mouthwashes or others.  A mucous cyst, also known as a mucocoele, is a fluid-filled swelling that arises on the lip or the mouth. Most cysts are on the lower lip but it can occur anywhere inside the oral cavity. Mucosal inflammation typically refers to inflammation or irritation of the mucus membranes. These are areas of the body which can produce mucus in an effort to filter out bacteria, viruses, and other intruders. This includes the nasal cavities, mouth, throat, eyes, vagina, lungs, and intestines. Inflammation can occur if bacteria or viruses cause an infection, if the area is cross by allergens or other foreign bodies, or due to fungal infection. The cyst grows when mucus from the mouth’s salivary glands becomes plugged. Some of the Skin diseases which associated with mucous membrane manifestations such as Pemphigus vulgaris, Lichen planus, Lupus erythematosus, Mucosal candidiasis, Viral diseases such as Koplik‘s spots of measles and herpes simplex, Syphilis.

Track 2: Vaccines Against Infectious Diseases and Cancers

Vaccines against infectious diseases represent a therapeutic vaccine against chronic infectious diseases aim at eliciting broad humoral and cellular immune responses against multiple target antigens. The development of these vaccines will help to establish substitute markers of protection in humans and thus will boost the subsequent development of capable prophylactic vaccines. A grouping of synthetic small-molecule drugs and immunotherapeutics is likely to represent a powerful means of controlling chronic infections in the future. There are a number of scientific challenges which require multidisciplinary teams to solve problems in developing new immunogens. This has challenged our existing knowledge about protein structure and conformation, microbial pathogenicity and the immune system. Cancer cells are generally ignored by the immune system. This is because for the most of the part are more closely resemble cells that belong in the body than pathogens, such as bacterial cells or viruses. The goal of cancer vaccines is to provoke the immune system to identify cancer cells as foreign and attack them.

Track 3: Allergic Asthma Treatment and Prevention

Asthma is a chronic condition in which the airways that carry air to the lungs are inflamed and narrowed. It’s caused by a combination of both genetic and environmental factors. Many genes have been related to asthma. Inflamed airways are very sensitive, and they tend to react to things in the environment called triggers, such as substances that are inhaled. When the airways react, they swell and narrow even more, and also produce extra mucus, all of which make it harder for air to flow to the lungs. The muscles around the airways also tighten, which further restricts air flow. There are also many environmental factors connected to asthma in children. With so many variables, preventing the development of asthma can be challenging, if not impossible. Immunotherapy in the form of allergy shots, works to enhance or suppress the immune system. The goal of immunotherapy is to reduce sensitivity to allergens over time.

Track 4: Child Vaccination & Immunization / Pediatric Vaccines

Children vaccines that ought to be administered to humans during childhood stage of life can be termed as childhood vaccines. These vaccines are primarily responsible for the induction of immune system and development of immunogenic response within the child. Immunisation protects people against harmful infections before they come into contact with them. Technically ‘vaccination’ is the term used forgiving a vaccine that is actually getting the injection or swallowing the drops. Immunisation is the term used for the process of both getting the vaccine and becoming immune to the disease as a result of the vaccine.

Track 5: Mucosal Immunology of Parasitic Diseases

The mechanisms controlling host microbe interactions at barrier sites such as the skin and the gut. These two sites represent the first portal of pathogen exposure and are major anatomical sites for development of inflammatory disorders. The skin and the gut also represent highly specialized environments with distinct structures, cell types, and innate defense mechanisms tailored to support their individual challenges.

Track 6: Veterinary Vaccines

The main goals of veterinary vaccines are to progress the health and welfare of companion animals, increase production of livestock in an economical manner, and prevent animal to human transmission from both domestic animals and wildlife. Animals, just like humans, suffer from a range of infectious diseases. As veterinary medicine has advanced, prevention of disease has become a priority. One of the best means of prevention is by creating immunity in the animal. This is usually achieved by vaccination. Vaccination also reduces the amount of pharmaceutical treatments (such as antibiotics) used to control conventional diseases and, in many instances, has prevented long term suffering and death.

Track 6: Mucosal Vaccination

Most infectious agents enter the body at mucosal surfaces and therefore mucosal immune responses function as a first line of defence. Protective mucosal immune responses are most effectively induced by mucosal immunization through oral, nasal, rectal or vaginal routes, but the vast majority of vaccines in use today are administered by injection. Immunisation involves the delivery of antigens to the mucosal immune system (dispersed or organised into units such as Peyer’s patches in the intestine or the nasal-associated lymphoid tissue in the oropharangeal cavity). The antigen delivery systems may comprise a simple buffer solution with/without adjuvants or an advanced particulate formulation, such as liposomes or nanoparticles. The most commonly evaluated route for mucosal antigen delivery is oral, but other routes have also been explored.

Track 7: Mucosal Vaccines Adjuvants

Mucosal immune responses are the first-line defensive mechanisms against a variety of infections. Consequently, immunizations of mucosal surfaces from which common of infectious agents make their entry, helps to protect the body against infections. Hence, vaccination of mucosal surfaces by using mucosal vaccines delivers the basis for generating protective immunity both in the mucosal and systemic immune compartments.Vaccines delivered through mucosal surfaces are increasingly studied because of their properties to effectively induce mucosal immune responses are cheap, easily administrable and suitable for mass vaccinations. 

Track 8: Mucosa Immunization Industries

Mucosal Immunization Industries capable of inducing protective immune responses both in the mucosal and systemic immune compartments has many advantages and is regarded as a blue ocean in the vaccine industry. Mucosal vaccines can offer lower costs, better accessibility, needle free delivery and higher capacity of mass immunizations during pandemics. Scientific achievements in innate immunity have been translated into the development of new mucosal adjuvants.

Track 9: Mucosal Melanoma

Track 10: Mucosal Immunology of HIV Infection

Recent advances in the immunology, pathogenesis, and prevention of human immunodeficiency virus (HIV) infection continue to reveal clues to the mechanisms involved in the progressive immunodeficiency attributed to infection.  HIV selectively infects, eliminates, and/or dysregulates several key cells of the human immune system, thwarting multiple arms of the host immune response, and inflicting severe damage to mucosal barriers, resulting in tissue infiltration of 'symbiotic' intestinal bacteria and viruses that essentially become opportunistic infections promoting systemic immune activation. Mucosal tissues are the major targets exposed to the HIV during transmission. In the majority of subjects the initial acquisition of HIV involves passage of virus across a mucosal surface. The sexual route is the most important route of transmission- (1) homosexuals where lymphoid cells are likely to be the prime target and (2) heterosexuals where the genital tract provides the virus access to lymphoid cells.

Track 11: Mucosal Immunity and Vaccines

There is currently great interest in developing mucosal vaccines against a variety of microbial pathogens. Mucosally induced tolerance also seems to be a promising form of immunomodulation for treating certain autoimmune diseases and allergies. Mucosal tissues (e.g. nasal, oral, ocular, rectal, vaginal) cover a large surface of the body. Since many infections are initiated at mucosal sites, it is critical to develop strategies for neutralising the infectious agent at these surfaces.

Track 12: Mucosal Immunology of Host Defenses

The Immunity and Host Defense section covers the interface between the Innate and acquired immune responses that protect the host from deleterious effects of pathogens, including basic mechanisms of immune responses to limit pathogen invasion and toxicity, and development of animal models of potential bioterrorism agents.

Track 13: Sinus Mucosal

The sinuses are hollow, bone and mucus lined spaces that lie just to the side of the nose and extend up to the bottom of our skull. There are several different sinuses in the human head and include two large paired maxillary (sometimes referred to as cheek sinuses), two frontal and sphenoid sinuses and multiple ethmoid sinuses. Sinus disease occurs in several forms, but all are related to a combination of infection and the inability of air to get into sinus cavities from the nose. Similar to the ear and mastoid, the sinuses are air-filled spaces surrounded by thin bone and lined by mucosa. When the air is absorbed by the mucosa faster than air can get through the sinus openings (ostia) into the sinuses, a relative vacuum develops and fluid is pulled from the lining tissues of the sinuses into the sinus cavities.  This fluid easily becomes infected.  Allergy causes mucous glands to release thicker fluids (mucous), which can also become infected and which are harder to clean from the sinuses. Sinus disease is not just one entity but many. Overall infectious or inflammatory sinus disease can be broken up into acute (quick onset) or chronic (over a long period of time). Acute sinusitis is the most common form of sinusitis and is typically treated with a combination of antibiotics and agents to decrease inflammation in the nose.

Track 14: Vaccine Delivery Systems

Mucosal surfaces are a major gateway for many human pathogens that are the cause of infectious diseases worldwide. Vaccines capable of eliciting mucosal immune responses can fortify defenses at mucosal front lines and protect against infection. However, most permitted vaccines are administered parenterally and fail to produce protective mucosal immunity. Immunization by mucosal routes may be more effective at inducing protective immunity against mucosal pathogens at their sites of entry. Recent advances in mucosal immunity and identification of correlates of protective immunity against specific mucosal pathogens have renewed interest in the development of mucosal vaccines.

Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.

Track 15: Mucosal Immunology of Infectious Diseases

Mucosal immunology is so important since most infectious agents enter the body through the various mucous membranes, and many common infections take place in or on mucous membranes. Mucosal infections induce mucosal and systemic immune response.

Track 16: Semaphorins as Regulators of Chronic Mucosal Inflammatory Conditions

Semaphorins are a large family of proteins involved in the pathogenesis of inflammatory diseases through the regulation of immune homeostasis and tissue inflammation. Several members of semaphorin family proteins have been recently defined as active and non-redundant players in the inflammatory response regulating immune cells, smooth muscle cells, endothelial cells and eosinophils.

Track 17: Mucosal Immunology in Urology

Urology is a surgical speciality that deals with the treatment of conditions involving the male and female urinary tract and the male reproductive organs. The organs under the domain of urology include the kidneys, adrenal glands, ureters, urinary bladder, urethra, and the male reproductive organs (testes, epididymis, vas deferens, seminal vesicles, prostate and penis).The field of urology involves the medical management of conditions such as urinary tract infection and prostate enlargement through to the surgical management of conditions such as bladder cancer, prostate cancer, kidney stones and stress incontinence.

Mucosal Immunology 2016

Conference series LLC hosted the “International Conference on Mucosal Immunology and Vaccine Development” during July 28-29, 2016 at Melbourne, Australia with the theme “Innovations and Novel Approaches in Mucosal Immunology” was a great success, where eminent keynote speakers from various reputed institutions and organizations with their resplendent presence addressed the gathering.

Benevolent response and active participation was received from the renowned experts and Editorial Board Members of Conference series Journals as well as from the Immunologists, Vaccinologist, Professors, Scientists, Researchers, Students and Leaders from the fields of Immunology and Vaccine, who made this event successful.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

·         Mucosal Diseases
·         Vaccines Against Infectious Diseases and Cancers
·         Allergic Asthma Treatment and Prevention
·         Veterinary Vaccines
·         Innate Immunity
·         Veterinary Vaccines
·         Child Vaccination & Immunization/Pediatric Vaccines
·         Mucosal Vaccination
·         Mucosal Vaccines Adjuvants
·         Mucosa Immunization Industries
·         Mucosal Immunology of HIV Infection
·         Mucosal Immunity and Vaccines
·         Mucosal Immunology of Infectious Diseases
·         Mucosal Immunology of Parasitic Diseases
·         Mucosal Immunology of Host Defenses

The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

·         Eric Cox, Ghent University, Belgium
·         William C Gause, Rutgers New Jersey Medical School, USA
·         Daisy Vanrompay, Ghent University, Belgium

All the above mentioned Honorable Guests and Keynote speakers gave their energetic and fruitful contributions and special thanks to our Honorable Moderator Damien John Zanker, La Trobe University, Australia for his remarkable contribution towards smooth functioning at Mucosal Immunology-2016 Conference.

Conference Sessions Chairs:

·                     Damien John Zanker, La Trobe University, Australia
·                     Makoto Yawata, National University of Singapore, Singapore

Conference Series LLC offers its heartfelt appreciation to Societies, Media Partners and Organizations includes Allied Academies, Andrew John Publishing Inc., New York Private Equity Forums and is also obliged to the Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who interlaced with Conference series LLC in supporting and making the conference a never before one.

With the valuable feedback and generous response received from the participants of the event, Conference Series LLC would like to announce the commencement of the “2nd Mucosal Immunology and Vaccine Development Conference” during July 13-14, 2017 at Chicago, USA.


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date July 13-14, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Conferenceseries Destinations